|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
2
|
Gupta S, Kong W, Peng Y, Miao Q and
Mackillop WJ: Temporal trends in the incidence and survival of
cancers of the upper aerodigestive tract in Ontario and the United
States. Int J Cancer. 125:2159–2165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weinstein IB, Joe A and Felsher D:
Oncogene addiction. Cancer Res. 68:3077–3080. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang SF, Cheng SD, Chien HT, Liao CT,
Chen IH, Wang HM, Chuang WY, Wang CY and Hsieh LL: Relationship
between epidermal growth factor receptor gene copy number and
protein expression in oral cavity squamous cell carcinoma. Oral
Oncol. 48:67–72. 2012. View Article : Google Scholar
|
|
5
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shintani S, Mihara M, Nakahara Y, Aida T,
Tachikawa T and Hamakawa H: Lymph node metastasis of oral cancer
visualized in live tissue by green fluorescent protein expression.
Oral Oncol. 38:664–669. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Klosek SK, Nakashiro K, Hara S, Goda H and
Hamakawa H: Stat3 as a molecular target in RNA interference-based
treatment of oral squamous cell carcinoma. Oncol Rep. 20:873–878.
2008.PubMed/NCBI
|
|
9
|
Shintani S, Hamakawa H, Nakashiro K,
Shirota T, Hatori M, Tanaka M, Kuroshita Y and Kurokawa Y: Friend
leukaemia insertion (Fli)-1 is a prediction marker candidate for
radiotherapy resistant oral squamous cell carcinoma. Int J Oral
Maxillofac Surg. 39:1115–1119. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mu P, Nagahara S, Makita N, Tarumi Y,
Kadomatsu K and Takei Y: Systemic delivery of siRNA specific to
tumor mediated by atelocollagen: Combined therapy using siRNA
targeting Bcl-xL and cisplatin against prostate cancer. Int J
Cancer. 125:2978–2990. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ochiya T, Takahama Y, Nagahara S, Sumita
Y, Hisada A, Itoh H, Nagai Y and Terada M: New delivery system for
plasmid DNA in vivo using atelocollagen as a carrier material: The
Minipellet. Nat Med. 5:707–710. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Minakuchi Y, Takeshita F, Kosaka N, Sasaki
H, Yamamoto Y, Kouno M, Honma K, Nagahara S, Hanai K, Sano A, et
al: Atelocollagen-mediated synthetic small interfering RNA delivery
for effective gene silencing in vitro and in vivo. Nucleic Acids
Res. 32:e1092004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Azuma K, Nakashiro K, Sasaki T, Goda H,
Onodera J, Tanji N, Yokoyama M and Hamakawa H: Anti-tumor effect of
small interfering RNA targeting the androgen receptor in human
androgen-independent prostate cancer cells. Biochem Biophys Res
Commun. 391:1075–1079. 2010. View Article : Google Scholar
|
|
14
|
Sasaki T, Nakashiro K, Tanaka H, Azuma K,
Goda H, Hara S, Onodera J, Fujimoto I, Tanji N, Yokoyama M, et al:
Knockdown of Akt isoforms by RNA silencing suppresses the growth of
human prostate cancer cells in vitro and in vivo. Biochem Biophys
Res Commun. 399:79–83. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Luo J, Manning BD and Cantley LC:
Targeting the PI3K-Akt pathway in human cancer: Rationale and
promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lim J, Kim JH, Paeng JY, Kim MJ, Hong SD,
Lee JI and Hong SP: Prognostic value of activated Akt expression in
oral squamous cell carcinoma. J Clin Pathol. 58:1199–1205. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Beck JT, Ismail A and Tolomeo C: Targeting
the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of
rapamycin (mTOR) pathway: An emerging treatment strategy for
squamous cell lung carcinoma. Cancer Treat Rev. 40:980–989. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gonzalez E and McGraw TE: The Akt kinases:
Isoform specificity in metabolism and cancer. Cell Cycle.
8:2502–2508. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lui VWY, Hedberg ML, Li H, Vangara BS,
Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, et al:
Frequent mutation of the PI3K pathway in head and neck cancer
defines predictive biomarkers. Cancer Discov. 3:761–769. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cohen Y, Goldenberg-Cohen N, Shalmon B,
Shani T, Oren S, Amariglio N, Dratviman-Storobinsky O,
Shnaiderman-Shapiro A, Yahalom R, Kaplan I, et al: Mutational
analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell
carcinoma. Oral Oncol. 47:946–950. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Naruse T, Yanamoto S, Yamada S, Rokutanda
S, Kawakita A, Kawasaki G and Umeda M: Anti-tumor effect of the
mammalian target of rapamycin inhibitor everolimus in oral squamous
cell carcinoma. Pathol Oncol Res. 21:765–773. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takeshita F, Minakuchi Y, Nagahara S,
Honma K, Sasaki H, Hirai K, Teratani T, Namatame N, Yamamoto Y,
Hanai K, et al: Efficient delivery of small interfering RNA to
bone-metastatic tumors by using atelocollagen in vivo. Proc Natl
Acad Sci USA. 102:12177–12182. 2005. View Article : Google Scholar : PubMed/NCBI
|
